NEBIDO + PLACEBO
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism
Trial Timeline
Oct 1, 2008 → Oct 1, 2008
NCT ID
NCT00710827About NEBIDO + PLACEBO
NEBIDO + PLACEBO is a approved stage product being developed by Bayer for Hypogonadism. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00710827. Target conditions include Hypogonadism.
What happened to similar drugs?
5 of 18 similar drugs in Hypogonadism were approved
Approved (5) Terminated (2) Active (12)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00710827 | Approved | Withdrawn |
Competing Products
20 competing products in Hypogonadism